Around the circle

Until recently, Cyclacel Ltd. has disclosed its clinical pipeline piece by piece, which can make it hard to see how the company's overall development strategy fits together. But Cyclacel's approach to exploiting the cell cycle is becoming more visible, so that investors now can see how the company is trying to create a portfolio of cancer drugs that ultimately should be synergistic with or complementary to each other and to other cancer therapies.

In addition, because the mechanism of action of most Cyclacel compounds also slows proliferation of normal cells, the strategy is generating opportunities in other indications, as illustrated by its programs in inflammation, diabetes and antivirals...